MENU
+Compare
ALPMY
Stock ticker: OTC
AS OF
Jul 3 closing price
Price
$9.60
Change
-$0.05 (-0.52%)
Capitalization
26.55B

ALPMY Astellas Pharma, Inc. Forecast, Technical & Fundamental Analysis

Astellas Pharma Inc is a specialty global pharmaceutical company... Show more

ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ALPMY with price predictions
Jul 03, 2025

ALPMY in downward trend: 10-day moving average moved below 50-day moving average on June 23, 2025

The 10-day moving average for ALPMY crossed bearishly below the 50-day moving average on June 23, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where ALPMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

ALPMY moved below its 50-day moving average on July 01, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALPMY entered a downward trend on July 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALPMY's RSI Oscillator exited the oversold zone, of 47 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 30, 2025. You may want to consider a long position or call options on ALPMY as a result. In of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALPMY just turned positive on June 30, 2025. Looking at past instances where ALPMY's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALPMY advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

ALPMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.427) is normal, around the industry mean (5.632). P/E Ratio (37.594) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.004). Dividend Yield (0.030) settles around the average of (0.161) among similar stocks. P/S Ratio (2.448) is also within normal values, averaging (3.643).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ALPMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.

View a ticker or compare two or three
ALPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ALPMY is expected to report earnings to fall 54.76% to 13 cents per share on July 30

Astellas Pharma, Inc. ALPMY Stock Earnings Reports
Q2'25
Est.
$0.13
Q1'25
Beat
by $0.16
Q4'24
Missed
by $0.41
Q3'24
Beat
by $0.01
Q2'24
Beat
by $0.08
The last earnings report on April 25 showed earnings per share of 29 cents, beating the estimate of 13 cents. With 41.05K shares outstanding, the current market capitalization sits at 26.55B.
A.I.Advisor
published Dividends

ALPMY paid dividends on June 17, 2024

Astellas Pharma, Inc. ALPMY Stock Dividends
А dividend of $0.22 per share was paid with a record date of June 17, 2024, and an ex-dividend date of March 27, 2024. Read more...
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
2-5-1, Nihonbashi-Honcho
Phone
+81 332443000
Employees
16243
Web
http://www.astellas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UGRO0.310.01
+3.23%
urban-gro
CFFI67.272.08
+3.19%
C&F Financial Corp
UTI32.300.70
+2.22%
Universal Technical Institute
IX22.890.07
+0.31%
Orix Corp
BTG3.66N/A
N/A
B2Gold Corp

ALPMY and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMY has been loosely correlated with ALPMF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMY jumps, then ALPMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMY
1D Price
Change %
ALPMY100%
-0.52%
ALPMF - ALPMY
37%
Loosely correlated
N/A
OPHLY - ALPMY
32%
Poorly correlated
-0.85%
OTSKY - ALPMY
21%
Poorly correlated
-1.50%
BAYRY - ALPMY
13%
Poorly correlated
-1.16%
ABBV - ALPMY
12%
Poorly correlated
-0.77%
More